Latest News

NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute

SYDNEY, May 15, 2019 /PRNewswire/ -- NeuClone Pharmaceuticals Ltd. (NeuClone), a clinical-stage b...

2019-05-15 20:13 1333

NeuClone Announces its Sixth Biosimilar Candidate Perjeta(R) (Pertuzumab) for use in Combination Therapy with Herceptin(R) (Trastuzumab)

SYDNEY, Dec. 17, 2018 /PRNewswire/ -- NeuClone Pharmaceuticals Ltd. (NeuClone), a clinical-stage bi...

2018-12-17 21:30 763

NeuClone Announces First Human Dose of Herceptin® (trastuzumab) Biosimilar Candidate in Phase I Clinical Trial

SYDNEY, Oct. 23, 2018 /PRNewswire/ -- NeuClone Ltd, a biopharmaceutical company exclusively focused...

2018-10-23 21:00 535

NeuClone Announces Preclinical Results for Stelara® (ustekinumab) Biosimilar Candidate

SYDNEY, May 10, 2018 /PRNewswire/ -- Biopharmaceutical company NeuClone has announced positive prec...

2018-05-10 20:00 999